Technology

Our technology platforms can lead to products that are easier to use for patients and caregivers, while reducing costs for payers and the healthcare system.

The Xeris Solution for Conventional Formulation Limitations

Our proprietary XeriSol and XeriJect non-aqueous formulation technology platforms are designed to address the limitations of aqueous formulations for certain drugs. The solutions or suspensions formulated using our technology have high stability and solubility.

HIGH STABILITY

No Syringe and Vial - no need for reconstitution

NO Reconstitution

Ready-to-use injectable, with straightforward administration.

Refrigerator

NO Refrigeration

Room-temperature stability, with no refrigeration required.

HIGH SOLUBILITY

Half-filled syringe indicating smaller injection volumes

SMALLER
Injection Volumes

Small injection volumes due to non-aqueous formulation.

Checkmark - Convenient administration

CONVENIENT Administration

Qualities allow for subcutaneous (SC) or intramuscular (IM) administration.

Our biocompatible non-aqueous injectable solutions or suspensions can be packaged for administration in various commercially available ways:

Vial

Vial

Auto-injector pen

Single-use
auto-injector

Prefilled syringe

Prefilled
syringe

Multi-dose auto-injector pen

Multi-dose
pen

Infusion pump

Infusion
pump

XeriSol can be used for smaller molecules

The XeriSol formulation technology is best suited for peptides and small molecules that encounter formulation challenges.

HOW IT WORKS

1

An aqueous formulation of a peptide or small molecule is created at an optimal, specific pH. This allows the peptide or small molecule to remain soluble at high concentrations in water.

2

The solution is dried into a powder and reconstituted in an aprotic, polar (FDA-approved) liquid. The liquid prevents aggregation and fibrillation of the drug substance.

3

When a ready-to-use XeriSol formulation is injected into a patient, it is effectively placed back into a water environment where it behaves appropriately.

XeriJect can be used for larger molecules

The XeriJect formulation technology is best suited for drugs and biologics consisting of large molecules such as proteins, monoclonal antibodies, and vaccines.

HOW IT WORKS

1

Specialized drying or particle engineering techniques are employed to create powders.

2

The powders are “wetted” with biocompatible diluents, creating ultra-concentrated, low-volume paste formulations.

3

The paste formulations are administered via IM or SC using commercially available pens and pumps.

Using XeriJect, we have formulated suspensions with a protein concentration in excess of 400 mg/mL, far exceeding current aqueous formulation systems with maximum achievable protein concentrations of 50–250 mg/mL. Our technology platforms can lead to products that are easier to use for patients and caregivers, while reducing costs for payers and the healthcare system.

Conventional Formulation Limitations

Injectable pharmaceuticals typically rely on liquid (water) to deliver drugs and biologics, but many drugs have low solubility in water and are not stable. There are a number of conventional approaches to address these barriers.

LOW STABILITY

Vial indicating need for reconstitution

Reconstitution

Products are freeze-dried into a powder that must be reconstituted with a liquid diluent prior to use. This is often a challenging multistep procedure, especially in emergency situations.

Refrigerator indicating need for refrigeration

Refrigeration

Reconstituted products may either need to be used immediately or refrigerated, because they begin to break down once combined with water.

LOW SOLUBILITY

Molecule indicating complicated formulations

Complicated Formulations

Products may require complicated formulation volumes to make them soluble.

Filled syringe indicating large injection volumes

Large Injection
Volumes

Products may require injection volumes that are too large for SC or IM delivery and therefore necessitate intravenous (IV) infusion.

BACK
TO TOP